(VIANEWS) – Shares of Eli Lilly and Company (NYSE: LLY) rose 8.08% to $336.23 at 10:39 EST on Wednesday, following the last session’s upward trend. NYSE is jumping 0.72% to $13,638.77, after five consecutive sessions in a row of losses. This seems, up until now, a somewhat positive trend trading session today.

Eli Lilly and Company’s last close was $311.10, 7.23% below its 52-week high of $335.33.

About Eli Lilly and Company

Eli Lilly and Company develops and markets pharmaceuticals for human use worldwide. Basaglar is available, as well as Humalog Mix 75/25 and Humalog U100. Humalog U200 and Humalog Mix 50/50. It also offers insulin lispro and insulin lispro protamine. Insulin lispro 75/25 and Humulin 70/30 and Humulin N and Humulin R for diabetes. Jardiance and Trulicity are offered for type 2. Alimta is available for the treatment of non-small-cell lung cancer. Olumiant is available for rheumatoid arthritis; Taltz can be used for plaque psoriasis and psoriatic arthritis. Cymbalta is available for depression, diabetes peripheral neuropathic, anxiety disorder and fibromyalgia; Emgality can prevent migraines and treat episodic cluster headaches; Zyprexa is for schizophrenia and bipolar I disorder; as well as bipolar maintenance. Bamlanivimab is available for COVID-19, as well as etesevimab and Bebtelovimab. Cialis can be used for benign prostatic hyperplasia and erectile dysfunction. Forteo treats osteoporosis. It has collaborations with Incyte Corporation, Boehringer Ingelheim Pharmaceuticals, Inc., Junshi Biosciences, Regor Therapeutics Group, Lycia Therapeutics, Inc., Kumquat Biosciences Inc., Entos Pharmaceuticals Inc., and Foghorn Therapeutics Inc.

Earnings Per Share

As for profitability, Eli Lilly and Company has a trailing twelve months EPS of $6.68.

PE Ratio

Eli Lilly and Company has a trailing twelve months price to earnings ratio of 50.33. Meaning,
the purchaser of the share is investing $50.33 for every dollar of annual earnings.

Return on Equity (TTM)

Eli Lilly and Company’s ROE is 74.02%.


Today’s last reported volume for Eli Lilly and Company is 3697240 which is 44.3% above its average volume of 2562066.

The company’s growth estimates for the ongoing quarter and the next is 5% and 11.7%, respectively.

Eli Lilly and Company’s Revenue

Year-on-year quarterly revenue growth grew by 14.8%, now sitting on 29.32B for the twelve trailing months.


Eli Lilly and Company’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.87%, a negative 0.06%, and a positive 1.43%, respectively.

Eli Lilly and Company’s highest amplitude of average volatility was 1.55% (last week), 1.60% (last month), and 1.43% (last quarter), respectively.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Eli Lilly and Company’s stock is considered to be overbought (>=80).

Eli Lilly and Company’s Stock Yearly Top and Bottom Value

Eli Lilly and Company’s stock is valued at $336.23 at 10:39 EST, above its 52-week high of $335.33.

Eli Lilly and Company’s Moving Average

Eli Lilly and Company’s value is above its 50-day moving average of $314.53 and way higher than its 200-day moving average of $288.72.

More news about Eli Lilly and Company (LLY).


Please enter your comment!
Please enter your name here